Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

Abstract: The inventive agent comprises polyclongal immunoglobulins of IgG class whose molecular mass is equal to 150 kD and which are obtainable in the form of a humoral immune response to an endothelial and mesenchymal stem cells complex.

Abstract: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.

Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Abstract: The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The compositions are optimized to elicit an immune response in a genetically-diverse population of individuals.

Abstract: A coated material and a process for producing the coated material which includes providing a coating agent comprising yeast cell wall fractions, as a primary constituent, consisting of cell residue of yeast which has been treated with enzymes, optionally subsequently with acidic solution, and water to remove internal soluble cell constituents; and coating a solid material with the coating agent to provide a coating thereon.

Abstract: A Tat-based tolerogen composition comprising at least one immunogenic antigen couplet to at least one human immunodeficiency virus (IIIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.

Abstract: The invention relates to compositions and methods for treating proliferative pathologies, in particular cancers. The invention is based on the identification of particular properties of TReP-132 in the control of the cell cycle and in the control of cell proliferation. Said protein behaves as a tumor suppressor and is therefore a preferred target for developing efficient therapeutic strategies. The invention also relates to compositions, uses and methods for identifying compounds which can modulate the activity of said protein, and which can be used for treating different proliferative pathologies, in particular in humans.

Abstract: The present invention relates to methods and compositions for manufacturing virus-like particles (VLPs), suitable for use as immunogens and as research tools. The VLPs of the present invention provide a sale alternative to the use of pathogenic viruses for clinical and laboratory applications.

Abstract: Provided herein are yeast cell particles (YCPs) comprising an antigen for use, e.g., as an oral, inhalation, mucosal or parenteral delivery vehicle for the antigen. A YCP may be obtained from a yeast cell by a process that removes at least some of the mannan from the outer cell wall layer, thereby exposing at least some of the cell wall ?-1,3-glucan. The antigen may be expressed in the form of a fusion of the protein antigen to a scaffolding protein sequence that will allow the antigen to aggregate in the yeast cytoplasm. Exemplary scaffolds include proteins, e.g., viral capsid proteins that assemble into virus-like particles in yeast cytoplasm and proteins or peptides that self-aggregate.

Abstract: The present invention discloses compositions and methods for the prevention and treatment of skin and hair diseases, such as, for example, alopecia, psoriasis, and keloids. The present invention also relates to compositions and methods for altering skin coloration. The present invention also relates to methods for enhancing the effect of a neurotoxin.

Abstract: There is disclosed vaccines formulated for administration to the mucosa of the lungs of a mammal, and the use thereof in methods for prophylaxis or treatment of an infection by at least one pathogenic microorganism. The vaccines comprise a cellular fraction of the microorganism that is essentially free of particulate matter and includes polyvalent soluble antigen from the microorganism.

Abstract: This invention relates to compositions comprising multi-haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such multi-haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma and ovarian adenocarcinoma cells are multi-haptenized, wherein the tumor cells are differentially haptenized either with a dinitrophenyl group coupled to ?-amino groups, or with a sulfanilic acid group coupled to aromatic side chains of histidine and tyrosine. A method of SA-haptenization is also provided.

Abstract: The specification and drawings describe and show one preferred embodiment or a small number of preferred embodiments of the present invention in the form of a container constructed from or lined with a material comprising a copolymer of acrylonitrile, methyl acrylate, and butadiene, said container defining an interior space constructed to contain therein, external to a patient's body, an inhalation anesthetic; and a volume of sevoflurane contained in said interior space defined by said container. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: The present invention relates to a method of applying makeup to keratinous substances, in particular such as the skin, the lips, the nails, or hair, the method comprising the following steps: depositing at least one cosmetic composition on keratinous substances, the cosmetic composition comprising: at least one body that presents non-zero magnetic susceptibility and that is movable under the effect of a magnetic field; and at least one coloring agent producing a color by absorbing at least a fraction of the visible spectrum; and exposing at least part of the composition to a magnetic field, so as to modify the orientation and/or displace at least some of the magnetic bodies.

Abstract: The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Abstract: A cosmetic polymer includes a water absorbent polymer, and a cosmetic ingredient encapsulated in the water absorbent polymer. Encapsulating a cosmetic ingredient in an absorbent polymer allows for systematic release of the cosmetic ingredient, thereby reducing the negative effects of preservatives found in many cosmetic ingredients.

Abstract: The invention provides compositions for attracting noctuid moths, which include at least one pheromone and at least one synergist. The synergist is a naturally-occurring phytochemical compound. The synergist is preferably ?-caryophyllene, iso-caryophyllene, ?-humulene, or combinations thereof. The invention also provides traps containing the composition for attracting noctuid moths, and methods for attracting, capturing, killing or sterilizing noctuid moths using the composition.

Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.

Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.

Abstract: Described is a medical device in the form of a thin sheet having granules of a calcium-containing, osteoconductive material interconnected by a thin web of polymeric material. The device includes a first face and a second face, wherein at least the first face is populated with proturbances presenting exposed regions of the calcium-containing, osteoconductive material provided by underlying granules. Methods of making and using such devices are also described, as are methods and devices involving the use of very thin polymeric sheets conformed to bone-ingrowth surfaces of load-bearing orthopedic implants.

Abstract: A sustained release apparatus including at least one sustained release mini-implant or pellet; the or each mini-implant or pellet including: a sustained release support material; and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s) providing, release of LHRH agonist and/or antagonist at, or above, a desired threshold level for treatment of a selected indication, the apparatus providing approximately zero order release of the LHRH agonist and/or antagonist.

Abstract: A base body contains a substrate that is at least partially coated with a carbon-containing layer. The carbon-containing layer is at least partially functionalized with a molecule that is bound directly or via at least one linker or functional group to the carbon-containing layer. The base body, which has a functionalized carbon-containing surface, is capable of influencing biological processes during a corresponding functionalization.

Abstract: A system for treating tissue carcinomas and benign inflammatory conditions of the urinary tract includes a flowable medium containing a bioactive agent and a thermogelling aqueous polymer solution. The thermogelling aqueous polymer solution maintains the bioactive agent within the urinary tract for a therapeutically optimal period of time. One embodiment includes delivering a bioactive agent in a flowable medium through an orifice into a body cavity, contacting the tissue to be treated with the bioactive agent, and filling the orifice of the body cavity with a thermogelling aqueous polymer solution. The polymer solution maintains the bioactive agent in contact with the tissue to be treated for a therapeutically optimal period of time.

Abstract: In the present invention, there are disclosed a therapeutic agent for the treatment of a disease in which the suppression of Thl cytokine production is therapeutically effective and/or a disease in which the suppression of autoantibody production is therapeutically effective, a therapeutic agent for the eradicative treatment of these diseases, and an agent for inhibiting the progress of these diseases, comprising (i) a proanthocyanidin with a polymerization degree of at least 4 or (ii) a plant material extract containing a proanthocyanidin as an active ingredient.

Abstract: The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

Abstract: A therapeutic agent and methodology for treatment of tonsillitis and tonsil, throat and mouth infection is provided as a combination of Lactic Acid and a delivery vehicle, such as an ingestible liquid. The agent is ingested by an individual with a spacing between applications thereof, such that recurrence of tonsil infection is suppressed.

Abstract: A method of membrane drying of bacterial cellulose, characterized by the fact that the membrane is stuck to a device and under tension, for acquirement of a dry pellicle with plain, flat and flexible structure.

Abstract: The present invention discloses general formula I of Temozolomide-8-carboxylate compounds, the process for preparation, pharmaceutical compositions comprising the compounds and the use of the compounds and pharmaceutical compositions for the manufacture of an antitumor medicament. The said pharmaceutical composition comprises one or more general formula I Temozolomide-8-carboxylate compounds as active ingredient, together with conventional pharmaceutical carriers. The composition also comprises one or more pharmaceutically acceptable acidic material, optionally second or tertiary alcohol or ester or ether derivatives thereof. The said pharmaceutical composition can be made into various common formulations, particularly oral formulations as well as topically transdermal patches. The present invention also discloses the application of the compounds and the compositions to treat tumor.

Abstract: An anti-microbial polymeric film comprising a polymeric substrate layer and an inorganic anti-microbial compound of formula (I): AgaHbAcM2(PO4)3.nH2O wherein: A is at least one ion selected from an alkali or alkaline earth metal ion; M is a tetravalent metal ion; a is in the range 0.4 to 0.5; b and c are positive numbers such that (a+b+mc)=1; m is the valence of metal A; and 0?n?6, wherein the anti-microbial compound is present in the substrate layer in an amount of from about 0.05 to about 0.7% of by weight of the polymeric material of the substrate layer; and the use of said inorganic anti-microbial compound for providing an antimicrobial polymeric film having reduced haze.

Abstract: Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins.

Abstract: A dermal patch includes a reservoir layer made of a polymer gel provided for receiving a liquid containing an active substance and having a first face to be applied onto the skin of a user in order to diffuse the active substance to the skin. The patch further includes a receiving layer for receiving the liquid containing the active substance and transmitting the liquid to the reservoir layer, and a layer of adhesive holding the receiving layer on a second face of the reservoir layer. The patch has the advantage of being rechargeable as required and can be manufactured without prior incorporation of the liquid containing the active substance into the reservoir layer.

Abstract: Transdermal delivery systems for delivery of Alzheimer's pharmaceuticals, particularly donepezil, over one to seven days are disclosed which deliver the free-base form of the Alzheimer's pharmaceutical at a skin permeation rate such that blood levels of the Alzheimer's pharmaceuticals are comparable to the approved oral dosage forms.

Abstract: Pharmaceutical compositions for transdermal administration containing a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfonic acid salt, an aryl sulfonic acid salt, or an alkyl aryl sulfonic acid salt of an unstable active agent, such as bupropion free base or a derivative of burpropion free base, such as bupropion free base or derivative of bupropion free base, paroxetine, fluvoxamine, fluoxetine, sertraline, venlafaxine, duloxetine, and metabolites and derivatives thereof are described herein. The composition may also contain one or more antioxidants. The compositions can be prepared by forming the bupropion salt followed by addition of the antioxidant. Alternatively, bupropion can be combined first with the antioxidant followed by addition of the acid to form the salt. The compositions can be administered as a gel, cream, lotion, ointment, or patch and typically contain a pharmaceutically acceptable carrier and optionally one or more pharmaceutically acceptable excipients.

Abstract: A bradykinin B2-receptor antagonist peptide, kinestatin, isolated from toad (Bombina maxima) defensive skin secretion, and analogs thereof, is disclosed. The structure of kinestatin is pGlu-Leu/Ile-Pro-Gly-Leu/Ile-Gly-Pro-Leu/Ile-Arg-NH2. Also disclosed are kinestatin analogs, prodrugs including the peptides, fusion peptides and multimeric peptides including the peptide sequences, pharmaceutical compositions including kinestatin and analogs thereof, prodrugs, fusion and multimeric peptides thereof, nucleic acids encoding kinestatin and analogs thereof, and nucleic acids encoding the fusion and multimeric peptides. Kinestatin and analogs thereof (including the prodrugs and multimeric and/or fusion peptides) can be used to treat and/or prevent disorders associated with bradykinin, including cardiovascular disorders, inflammation, asthma, allergic rhinitis, pain, angiogenesis and the like.

Abstract: This invention relates to encapsulation of drugs and other agents into liposomes.

Abstract: The present invention provides a novel method for the treatment of cellular accumulation in chronic inflammatory diseases such as rheumatoid arthritis. The method includes gene delivery and gene expression that is capable of enhancing apoptosis of accumulating cells and those cells which recruit accumulating cells. Also provided are diagnostic methods for detecting cellular accumulation diseases.

Abstract: The present invention relates to optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.

Abstract: The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.

Abstract: The present invention relates to a method for the preparation of bioavailable dosage form of modafinil.

Abstract: A rapidly dispersible, fine-particle film-coating composition which is in powder form and is not prone to segregation for coating pharmaceutical dosage forms, consisting of a) 40-90% by weight of a polyvinyl alcohol-polyether graft copolymer (component A), b) 1-20% by weight of a polyvinylpyrrolidone or of a vinylpyrrolidone-vinyl acetate-copolymer with a K value of from 10 to 100 (component B) c) 10-60% by weight of organic or inorganic pigments having an average particle size of less than 8 ?m (component C) d) 0.5-15% by weight of a surfactant having an HLB of greater than 10 (component D) and e) 0-30% by weight of further customary coating ingredients (components E), in which the particles of component C are embedded in a coherent polymer matrix, where the total amount of components A to E is 100% by weight.

Abstract: A pharmaceutical preparation comprising: a) a core with an active ingredient and with an organic acid and/or the salt of an organic acid; and b) a coating which envelops the core and which comprises a polymer content of (meth)acrylate copolymers which have not more than 15% by weight of cationic or anionic groups, and which comprises at least 60% by weight of a (meth)acrylate copolymer which is composed of free-radically polymerized units of 93 to 98% by weight C1- to C4-alkyl esters of acrylic or of methacrylic acid and 7 to 2% by weight (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, wherein the active ingredient has a solubility in water of at least 10 g/l at 20° C. and the coating comprises silicon dioxide particles having an average particle size in the range from 1 to 50 ?m.

Abstract: Novel neuroprotectant compositions and methods are described. ?-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult.

Abstract: Disclosed are photoresponsive hydrogels. The compositions disclosed herein can be prepared by polymerizing a hydrogel precursor and a spiropyran. The properties of the disclosed compositions can be changed by exposure to light, pH, and temperature. Methods of using the disclosed compositions to deliver pharmaceutical actives are also disclosed.

Abstract: This invention relates to methods of treating mammals at risk or affected by central nervous glial scarring by administering a cyclosporine component. Among the conditions treated are, but not limited to, epidural scarring, meningeal fibrosis, arachnoiditis, nerve root tethering, brain and spinal cord injury, as well as peripheral nerve, tendon and ligament scarring.

Abstract: The present invention relates to dispersions of nanoureas comprising biologically active compounds, a process for their preparation, and their use.

Abstract: A process for obtaining a microscopic physical state of xanthophylls or oxycarotenoids derivatives forms such as diacetates or dipropionates derivatives, which are readily incorporated in the digestive system as micelles providing an improved bioavailability, as compared to the bioavailability of carotenoids that are ingested in diverse preparations that contain microscopic carotenoids crystals and a method for its application.

Abstract: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

Abstract: An adsorbent for an oral administration, comprising a spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, and a bulk density is less than 0.54 g/mL is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.

Abstract: Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.